Introduction
Tuberculosis (TB) is still a worldwide deadly threat despite global and national control programs. Every year there are two million TB-related deaths globally. 1 The global TB mortality rate was 29/100,000 in 1990 and increased to peak at 32/100,000 in 2000 before decreasing to 27/100,000 in 2007. 2 After a decades-long battle against TB, the World Health Organization (WHO) has set the goal to reduce TB mortality below 15 per 100,000 by 2015.
TB mortality rate is different in developing and developed countries. A Centers for Disease Control and Prevention surveillance report in 2008 showed that TB mortality in the United States was 0.2 per 100,000. 3 In contrast, Thailand, which was ranked 18th of the top 22 highest TB-burdened countries, had a mortality rate of 21/100,000 in 2007. and 9% in 2007, which were the highest proportions in the WHO Southeast Asian region. These figures were very similar to the proportion of TB patients' deaths (8%) reported by the European region, which was the highest among all WHO regions in 2007. 5 Chiang Rai province, the study site of the current study, is a TB and HIV endemic area. It has a higher TB case fatality rate (17.1%) than its neighboring provinces in Northern Thailand. 6 Previous literature has stated that living in Chiang Rai province itself is a risk factor of death among TB patients (adjusted relative risk 2.7). 7 TB is a chronic communicable disease that is curable. Moreover, TB death is preventable. To aid prevention, it is necessary to specify the time, place, and persons at higher risk of death. Identifying the time when most TB deaths occur during the course of treatment is necessary. Characteristics of patients who died of TB during that high-risk period should be observed to specify social and clinical risk groups of TB death.
We aimed to find out the time of highest on-treatment death along the timeline of TB treatment. Furthermore, we tried to identify the characteristics of TB patients who died during that high-risk period.
Material and methods

Data collection and source
TB surveillance data were used for the study. The study was approved by Chiang Rai Ethical Committee and Chiang Rai Provincial Health Office, Thailand. TB surveillance data covered 17 hospitals in Chiang Rai province.
study population
The study population comprised TB patients selected based on the following criteria. These criteria were applied for both parts of the analysis. 
Inclusion criteria
TB treatment
TB patients in Chiang Rai province were treated according to National TB Program treatment guidelines. Choice of TB treatment regimen was based on the criteria of new case, retreatment, and drug resistance regimen according to the treatment category in the WHO guidelines. 8 
Death
Death from any cause during TB treatment was listed as on-treatment TB death according to the WHO TB treatment outcome definition. 8 Death during TB treatment was confirmed by using hospital records and the death registry in the online national vital status database.
Laboratory tests
Microscopic examination of sputum samples for acid-fast bacilli by Ziehl-Neelsen stain was carried out in the mycobacterial laboratory of each hospital in Chiang Rai province. Bacteriological diagnosis of tuberculosis culture was done at the mycobacterial laboratory of the Chiang Rai provincial hospital. Throughout the study period, solid culture via Ogawa medium was used. Figures 1A-1C) .
A total of 5,009 deaths occurred among 19,174 reported TB patients within 12 years. The events of death were analyzed against the timeline of TB treatment using smooth hazard risk estimation. The probability of death in the timeline of TB treatment was extrapolated by Kernel smoothed hazard rates estimation curve (Figure 2) .
Backward multilogistic regression analysis was performed to identify factors associated with the TB patients who died within the first month. Factors that contributed to 534 TB patients' deaths in the first month of treatment were investigated and compared with 5,092 survivors. Multiple logistic regression was restricted to variables with a P value less than 0.1 in bivariate analysis. Gender, age, race, marital status, education, occupation, BCG scar, patient type based on treatment regimen, and HIV status were included in multilogistic regression. A P value less than 0.05 was considered statistically significant, with a 95 percent confidence interval (CI) to determine adjusted odds ratio (aOR). The result of time-event analysis by Kernel smoothed hazard rates estimation curve revealed higher probability of TB death in the first month ( Figure 2 ). The trend of TB deaths can be seen to decline over the timeline of TB treatment.
Results
First part of the analysis
second part of the analysis
Analysis of factors associated with TB deaths in the first month included 5626 TB patients. The basic characteristics of patients are shown in Table 1 . The proportion of male patients was higher than female patients. More than 85% The results of bivariate and multivariate analysis are shown in Table 2 . Age group, HIV status, and being a Thai citizen were significant risk factors associated with death in the first month of TB treatment after adjustment by multivariate analysis. The risk of death in the first month of TB treatment was found to be higher with advancing age (Figure 3 ).
Adjusted odds ratio were: aOR 17. 
Discussion
Time of highest on-treatment TB death
Death caused by TB is preventable. Management and care can be modified at the time of highest risk for death. Many researches and reports have discussed TB mortality and factors associated with TB mortality. Usually, all TB deaths are summarized as one of the treatment outcomes at the end of TB treatment. There is still a gap in the evidence needed to know the time of highest mortality.
Our observation of surveillance data over 12 years revealed that the highest proportion of TB deaths happened during the first month of TB treatment. The finding was persistent for more than a decade ( Figures 1A-1C) . The number of overall deaths became lower during the later 4 years 2005-2008. During 1997-2000, there was a lack of antiretroviral therapy (ART) for TB-HIV co-infected patients in Chiang Rai. After 2000, ART was provided by a national program, and access to ART was expanded with time. This may have led to an overall decline in the death rate in later years of observation. Nevertheless, the proportion of deaths was still the highest in the first month of TB treatment ( Figures 1A, 1B, and 1C) .
Harries et al identified in 1997 that 40% of TB deaths occurred in the first month of TB treatment in Malawi. 9 It was an interesting report, with particular observation of the time of highest death during TB treatment. The percentage of death in the first month was very similar to our observation. The finding was based on 1-year data from the TB registry in 1997 from 38 hospitals in Malawi. It would be more informative to see the trend of TB deaths in subsequent years, because 
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TB death in northern Thailand there were many changes, such as HIV prevalence, TB control activity, and policy. In our report, the proportion of TB deaths in the course of treatment can be seen serially for 12 years.
The same author in 2001 reported 40%-45% of all TB deaths in the first month of TB treatment regardless of daily or intermittent regimens in Malawi. 10 All these studies were at the same site, Malawi, which is a TB and HIV endemic area in Africa. Sub-Saharan Africa has a very high HIV prevalence that considerably fuels the TB death rates. However, other WHO regions, such as Southeast Asia and Europe, currently have a different HIV prevalence and TB epidemiology from those of Sub-Saharan Africa.
Our observation in Northern Thailand has identified the first month of TB treatment as the time of highest risk for TB death. The same pattern has continued consecutively for more than a decade. Therefore, it would be practical to launch interventions focusing on the first month of TB treatment in order to cut mortality. Our finding is expected to be applicable in many countries with similar TB epidemiology and problems globally.
Factors related to death in first month of TB treatment
Factors particularly associated with TB death in the first month of treatment were investigated to identify at-risk groups of patients. Clinical, laboratory, and sociodemo-graphic factors were analyzed. We found that advancing age, HIV infection, and being Thai were strongly associated with death in the first month of TB treatment.
Previously, studies across the world have shown the factors associated with TB mortality. Mostly, factors associated with treatment outcome death were reported. A few studies pointed out the risk factors for early death. Even before the HIV pandemic, early TB death and an association with older patients were stated in England and Wales. 11 A low body mass index less than 17.0 kg/m 2 was also revealed as a risk factor for early mortality. 12 A later study in Africa reported a higher death rate in HIV-positive TB patients. 13 Our result has shown the higher risk of early TB death with advancing age. The death rate in the first month specified by age groups increased with advancing age (Table 1) . AOR increased progressively with advancing age (Figure 3) . TB patients aged above 65 years were found to have the highest risk compared with other adult age groups (aOR 17.71, 95% CI 8.54-36.73).
Previous studies in various regions of the world reported high risk for elderly TB patients, but the risk was not specified for death in the first month. 7, 11, [14] [15] [16] [17] [18] [19] Recently, analysis of TB surveillance data from 15 European Union (EU) countries during 2002-2004 reported that advancing age and resistance to isoniazid and rifampicin were the strongest risks of TB death. 19 Therefore, our finding agreed with existing evidence for those at high-risk of TB death. Moreover, we specified the most likely time of death for these high-risk patients. However, the WHO definition of TB death covered death from any cause during TB treatment. Elderly TB patients might have comorbid diseases. Thus, it is difficult to claim TB as the sole contributor of death.
Currently, TB and HIV are two of the deadliest chronic infections globally. 20 In our study cohort from 2005-2008, 31% of all the TB patients were HIV positive. Among the deaths of patients during the first month, 35.6% were HIV positive (Table 1) . HIV-infected TB patients have significant risk for death in the first month of TB treatment. The aOR was 3.24 (2.46-4.26) . Unidentified status of HIV infection was also a risk factor for earlier TB death.
Previous studies have stated that HIV infection is an important risk factor for TB mortality. [21] [22] [23] Early deaths of TB-HIV co-infected patients were more likely caused by TB rather than other opportunistic infections.
21 CD4 cell depletion is a possible explanation for the higher death rates in HIV-positive TB patients. Consequently, timely ART would be an important factor. Moreover, adverse effects are common because of interaction between antiretroviral drugs and anti-TB drugs.
Historically, TB was said to be a disease of poor people. The risk of TB death and its time of occurrence could be related to socioeconomic factors. However, in our analysis, occupation and educational status of the patients were not significant after adjustment with a multilogistic regression model. Final analysis showed that being a Thai citizen is a significant risk factor. A similar observation was reported in a European study and was explained as the healthy migrant effect. 19 Bacteriological factors related to causal organism like culture positivity, drug resistance, and multidrugresistant TB (MDR-TB) were not significant factors in the current study. However, previous studies in Thailand and Europe reported that MDR-TB was a significant risk for overall TB death. 7, 19 The different finding could be due to a different time point of analysis and low level of MDR-TB prevalence in Chiang Rai.
More complete clinical data should be analyzed to identify risk groups who could die earlier. Recently, a study of 311 hospitalized TB patients in Brazil reported high mortality rates among hospitalized TB patients in a highly HIV prevalent setting. Respiratory failure requiring mechanical ventilation, smear negative sputum, and consolidation in chest X-ray are identified as predictors of in-hospital death. 24 It was a limitation of our study that we could not explore much about the factors related to anti-TB drugs, which were in fact a constant exposure in the study cohort. Most of our study cohort (more than 85%) comprised new cases treated by a WHO category I regimen 8 (Table 1) . Daphne and colleagues have reported that the occurrence of serious side effects of anti-TB drugs were more common in patients aged over 65 years and in HIV-positive patients. 25 In the past, one of the inclusion criteria of clinical trials was patients' age to be between 15 and 65 years. 26 Therefore, it is hard to know about adverse events in TB patients aged above 65 years. Further studies of decades-old TB regimens in elderly patients would be necessary.
The time of highest TB deaths was found to be the earlier period in TB treatment. Delayed diagnosis and late presentation may be associated with early TB death. However, a study in Vietnam reported that diagnostic delay was not associated with TB treatment outcome mortality. 18 Prospective studies beyond the scope of surveillance, based on contemporary evidence, should be assembled in future.
suggestions and proposed strategies Our analysis showed that elderly patients and HIV coinfected patients were the people at higher risk for early TB death. Elderly patients can have other allied illnesses, such as malignancy, other respiratory infections, and underlying liver diseases, which may lead to earlier TB death. A hospital-based prospective study focusing on the elderly and further analysis of more complete information on cause of death is necessary. A careful start to the administration of anti-TB drugs with a body weight-based adjusted dose, complete baseline clinical and laboratory investigations, and more frequent follow-ups are necessary. A TB hospital providing meticulous care of high-risk patients at the initiation of TB treatment in such an endemic area may be fruitful to save these risk groups.
To prevent early TB death in TB-HIV co-infected patients, ART coverage and access to ART is crucial in all settings, as the decline of overall death rate in later years of our observation has shown ( Figure 1C) . During the 12 years of the current study period, up to 2008, Thailand national guidelines recommended deferring ART in TB-HIV coinfection until 2 months after initiation of TB treatment in cases with CD4 count more than 200 cells/ul. 27, 28 New national guidelines for Thailand in 2010 changed the recommendation to start ART earlier but still, to defer ART if CD4 count is above 350 cells/ul. 29 Current international guidelines recommend starting ART in HIV infected persons with active TB disease irrespective of their CD4 count. 30,31. This strategy would help to reduce the early TB deaths in TB-HIV patients.
In conclusion, current study findings are useful clues for launching realistic prevention strategies against TB deaths in many countries. Across the course of TB treatment, the first month sees the highest number of TB deaths. During that first month, elderly patients and HIV-infected patients are at significantly high risk of death. It is expected that prioritizing interventions focused on high-risk times and high-risk patients will diminish mortality related to TB globally.
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